NorthWest Biotherapeutics Inc (NWBO)

[dr_lowenstein]

hmmmm this is interesting

The phase 3 DCVax trial (NCT00045968) investigated the impact of DCVax-L in addition to SOC (surgical resection and chemoradiotherapy) for newly diagnosed GBM patients. Due to the cross-over study design, nearly 90% of the patients in this study received DCVax-L, making an interpretation of the survival outcome challenging. In the overall intent to treat the patient population (investigational arm + control arm), the mOS was estimated to be 23.1 months. This study has benchmarked these findings to historical controls but has not yet evaluated its primary endpoint of PFS [62]. A recent phase 1 trial focused on an autologous DC vaccine pulsed with GBM stem-like cell line lysate, which was shown to be tolerable (NCT02010606). Further results are pending [63].